Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, the Netherlands.
College of Medicine and Public Health, School of Medicine, Flinders University, Adelaide, Australia.
Patient Educ Couns. 2021 Jan;104(1):163-170. doi: 10.1016/j.pec.2020.06.015. Epub 2020 Jun 18.
Identifying patient characteristics predicting categories of patient adherence to Chronic Obstructive Pulmonary Disease (COPD) exacerbation action plans.
Data were obtained from self-treatment intervention groups of two COPD self-management trials. Patients with ≥1 exacerbation and/or ≥1 self-initiated prednisolone course during one-year follow-up were included. Optimal treatment was defined as 'self-initiating prednisolone treatment ≤2 days from the onset of a COPD exacerbation'. Predictors of adherence categories were identified by multinomial logistic regression analysis using patient characteristics.
145 COPD patients were included and allocated to four adherence categories: 'optimal treatment' (26.2 %), 'sub optimal treatment' (11.7 %), 'significant delay or no treatment' (31.7 %), or 'treatment outside the actual exacerbation period' (30.3 %). One unit increase in baseline dyspnoea score (mMRC scale 0-4) increased the risk of 'significant delay or no treatment' (OR 1.64 (95 % CI 1.07-2.50)). Cardiac comorbidity showed a borderline significant increased risk of 'treatment outside the actual exacerbation period' (OR 2.40 (95 % CI 0.98-5.85)).
More severe dyspnoea and cardiac comorbidity may lower adherence to COPD exacerbation action plans.
Tailored self-management support with more focus on dyspnoea and cardiac disease symptoms may help patients to better act upon increased exacerbation symptoms and improve adherence to COPD exacerbation action plans.
确定预测慢性阻塞性肺疾病(COPD)加重行动计划患者依从性类别的患者特征。
数据来自两项 COPD 自我管理试验的自我治疗干预组。在一年的随访中,纳入≥1 次加重和/或≥1 次自行启动泼尼松龙治疗的患者。最佳治疗定义为“COPD 加重发作后≤2 天自行启动泼尼松龙治疗”。采用多变量逻辑回归分析,根据患者特征确定依从性类别的预测因素。
共纳入 145 例 COPD 患者,并分为 4 个依从性类别:“最佳治疗”(26.2%)、“次优治疗”(11.7%)、“明显延迟或无治疗”(31.7%)或“治疗不在实际加重期”(30.3%)。基线呼吸困难评分(mMRC 量表 0-4)增加一个单位,“明显延迟或无治疗”的风险增加(OR 1.64(95%CI 1.07-2.50))。合并心脏疾病显示“治疗不在实际加重期”的风险略有增加(OR 2.40(95%CI 0.98-5.85))。
更严重的呼吸困难和心脏合并症可能会降低 COPD 加重行动计划的依从性。
针对呼吸困难和心脏疾病症状的个体化自我管理支持可能有助于患者更好地应对加重症状,并提高 COPD 加重行动计划的依从性。